ClinicalTrials.gg
CompletedNCT00063154Updated Jul 7, 2015Results posted

Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy

A Phase 2 interventional study of Pertuzumab in Non-small Cell Lung Cancer, sponsored by Genentech, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-07.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche — 5 open to participants now, 16 under way, 8 of them phase 3. Carcinoma, Non-Small-Cell Lung · Hoffmann-La Roche.

Enrollment
104th of 142
51 · median 136
Started
2003
the only one that year
Phase 2
56 of 182
none open now
Registered
2nd of 182
by date

Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 104th largest by enrollment of the 142 interventional ones that give a count, is the only one that started in 2003, is one of 56 in phase 2, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the study drug pertuzumab is effective in treating patients with advanced lung cancer that has recurred following prior chemotherapy.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Tumor accessible to and willingness to undergo tumor biopsy
  • Age >= 18 years
  • Recurrent, documented NSCLC, i.e., squamous cell, adeno-, or large cell anaplastic carcinoma. A cytologic diagnosis is acceptable (i.e. fine-needle aspiration or pleural fluid cytology).
  • with at least one lesion that can be accurately measured in at least one dimension (bilateral dimensions should be recorded). Each lesion must be >= 20 mm when measured by conventional techniques, including palpation, plain X-ray, CT, and MRI, or >= 10 mm when measured by spiral CT.
  • Progression of disease during, or after completion of, at least one prior chemotherapy regimen, which should have contained either a platinum, a taxane or a vinca alkaloid (e.g. vinorelbine). There is no upper limit on the number of prior chemotherapy regimens each subject may have received.
  • Recovery from reversible acute effects of prior chemotherapy regimens or radiotherapy to NCI-CTC Grade \<= 1 (excluding alopecia)
  • performance status of 0 or 1
  • Use of an effective means of for men, or for women of
  • >= 1500/mL, count of >= 75,000/mL and >= 9 g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors; darbepoetin [Aranesp] is permitted)
  • Serum \<= 1.5 x the (ULN) and alkaline phosphatase, , and ALT \<= 2.5 x ULN (ALT, AST, and alkaline phosphatase \<= 5 x ULN for subjects with liver )
  • Serum creatinine \<= 1.5 x ULN
  • Internalized normalized ratio () \< 1.5 and activated partial thromboplastin time (aPTT) \< 1.5 ULN (except for subjects receiving warfarin)

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any HER pathway inhibitors (e.g., Herceptin [Trastuzumab], Iressa [gefitinib], Tarceva [erlotinib hydrochloride], C225, CI1033, TAK165
  • Treatment with other experimental anti-cancer agents within 4 weeks prior to Day 1
  • documented bronchioalveolar carcinoma
  • History or clinical or radiographic evidence of central nervous system or
  • , determined by ECHO, \<50%
  • Uncontrolled hypercalcemia (> 11.5 mg/dL)
  • Prior exposure of > 360 mg/m2 doxorubicin or liposomal doxorubicin, > 120 mg/m2 mitoxantrone, or > 90 mg/m2 idarubicin
  • Ongoing treatment, except for subjects who are on stable doses of \< 20 mg of prednisone daily (or equivalent), or for subjects who are taking corticosteroids for non-malignant conditions
  • History of other within 5 years of Day 1 except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, or basal or squamous cell skin cancer
  • History of serious systemic disease, uncontrolled hypertension (diastolic blood pressure > 100 mmHg on two consecutive occasions), unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i.e., atrial fibrillation, paroxysmal supraventricular tachycardia, or controlled hypertension are eligible)
  • Ongoing liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  • Active infection requiring IV antibiotics
  • Known infection
  • Pregnancy or lactation
  • Major surgery or significant traumatic injury within 3 weeks prior to Day 1, with the exception of tumor for the purposes of the study
  • Inability to comply with study and follow-up procedures
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Pertuzumab

    Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year (up to 17 treatment cycles). Subjects received pertuzumab at a loading dose of 840 mg in Cycle 1 followed by a dose of 420 mg in Cycles 2 and beyond.

    Drug: Pertuzumab

Interventions

  • Pertuzumab was supplied as a single-use liquid formulation.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)

    A best overall response could occur at any time during the study and was determined by Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions (TL) or the disappearance of all non-TLs and normalization of tumor marker level. A PR was defined as at least a 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the treatment started for TLs and the persistence of 1 or more non-TL(s) and/or the maintenance of tumor marker level above normal limits. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started or the appearance of one or more new lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.

    Time frame: Baseline to the end of the study (up to 1 year)

Secondary outcomes

  1. Number of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) With HER2 Phosphorylation + or - Tumors

    A best overall response could occur at any time during the study and was determined by Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions (TL) or the disappearance of all non-TLs and normalization of tumor marker level. A PR was defined as at least a 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the treatment started for TLs and the persistence of 1 or more non-TL(s) and/or the maintenance of tumor marker level above normal limits. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started or the appearance of one or more new lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.

    Time frame: Baseline to the end of the study (up to 1 year)

  2. Progression-free Survival

    Progression-free survival was defined as the time from the first day of pertuzumab treatment (Cycle 1, Day 1) to the time of documented disease progression (per RECIST) or death, whichever occurred first.

    Time frame: Baseline to the end of the study (up to 1 year)

  3. Number of Participants Free From Disease Progression at 3, 6, and 12 Months

    Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of longest diameter recorded since the treatment started or the appearance of one or more new lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: Baseline to the end of the study (up to 1 year)

07

Results

Posted Jun 8, 2015

Participant flow

Participant flow — Overall Study
MilestonePertuzumab
Started51
Completed0
Not completed51
Withdrew: Disease progression27
Withdrew: Adverse event2
Withdrew: Physician decision10
Withdrew: Death3
Withdrew: Reason unspecified1
Withdrew: Did not receive treatment8

Outcome measures

PrimaryPercentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)

A best overall response could occur at any time during the study and was determined by Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions (TL) or the disappearance of all non-TLs and normalization of tumor marker level. A PR was defined as at least a 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the treatment started for TLs and the persistence of 1 or more non-TL(s) and/or the maintenance of tumor marker level above normal limits. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started or the appearance of one or more new lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.

Time frame:
Baseline to the end of the study (up to 1 year)
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)
percentage of participantsPertuzumab
Complete response0.0
Partial response0.0
Stable disease51.4
Progressive disease48.6
SecondaryNumber of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) With HER2 Phosphorylation + or - Tumors

A best overall response could occur at any time during the study and was determined by Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions (TL) or the disappearance of all non-TLs and normalization of tumor marker level. A PR was defined as at least a 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since the treatment started for TLs and the persistence of 1 or more non-TL(s) and/or the maintenance of tumor marker level above normal limits. PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since the treatment started or the appearance of one or more new lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.

Time frame:
Baseline to the end of the study (up to 1 year)
Reported as:
Number · participants
Number of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) With HER2 Phosphorylation + or - Tumors
participantsPertuzumab
Complete response pHER2+ (n=4)0
Partial response pHER2+ (n=4)0
Stable disease pHER2+ (n=4)2
Progressive disease pHER2+ (n=4)1
No tumor assessment pHER2+ (n=4)1
Unable to evaluate response pHER2+ (n=4)0
Complete response pHER2- (n=34)0
Partial response pHER2- (n=34)0
Stable disease pHER2- (n=34)15
Progressive disease pHER2- (n=34)13
No tumor assessment pHER2- (n=34)5
Unable to evaluate response pHER2- (n=34)1
SecondaryProgression-free Survival

Progression-free survival was defined as the time from the first day of pertuzumab treatment (Cycle 1, Day 1) to the time of documented disease progression (per RECIST) or death, whichever occurred first.

Time frame:
Baseline to the end of the study (up to 1 year)
Reported as:
Median · weeks
Progression-free Survival
weeksPertuzumab
Progression-free Survival6.6 (6.0 to 14.7)
SecondaryNumber of Participants Free From Disease Progression at 3, 6, and 12 Months

Disease progression was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of longest diameter recorded since the treatment started or the appearance of one or more new lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
Baseline to the end of the study (up to 1 year)
Reported as:
Number · participants
Number of Participants Free From Disease Progression at 3, 6, and 12 Months
participantsPertuzumab
3 months8
6 months1
9 months0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab—15/43 (34.9%)42/43 (97.7%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPertuzumab
PNEUMONIAInfections and infestations7/43
CELLULITISInfections and infestations1/43
SEPSISInfections and infestations1/43
ACUTE RESPIRATORY DISTRESS SYNDROMERespiratory, thoracic and mediastinal disorders1/43
DYSPNOEARespiratory, thoracic and mediastinal disorders1/43
HYPOXIARespiratory, thoracic and mediastinal disorders1/43
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders1/43
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders1/43
PERICARDIAL EFFUSIONCardiac disorders1/43
NAUSEAGastrointestinal disorders1/43
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPertuzumab
FATIGUEGeneral disorders16/43
DIARRHOEAGastrointestinal disorders15/43
NAUSEAGastrointestinal disorders8/43
ANOREXIAMetabolism and nutrition disorders8/43
PAINGeneral disorders6/43
COUGHRespiratory, thoracic and mediastinal disorders6/43
DYSPNOEARespiratory, thoracic and mediastinal disorders6/43
ANXIETYPsychiatric disorders6/43
VOMITINGGastrointestinal disorders5/43
ARTHRALGIAMusculoskeletal and connective tissue disorders5/43

Baseline characteristics

Safety population: All participants who received any amount of pertuzumab.

Age, Continuous
Age, Continuous(years)Pertuzumab
Mean62.5 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab
Female17
Male26
08

Study locations

8 sites
  • Arizona Cancer Center
    Scottsdale, Arizona 85258, United States
  • Arizona Cancer Center
    Tucson, Arizona 85724-5024, United States
  • Cedars-Sinai Comprehensive Cancer Center
    Los Angeles, California 90048, United States
  • University of California Davis Cancer Center
    Sacramento, California 95817, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Memorial-Sloan Kettering Cancer Center
    New York, New York 10021-6007, United States
  • Vanderbilt Ingram Cancer Center
    Nashville, Tennessee 37232-5536, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 10 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2003
First posted
Jun 25, 2003
Start
Jul 2003
Primary completionActual
Apr 2005
CompletionActual
Apr 2005
Results first posted
Jun 8, 2015
Last update
Jul 7, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00063154
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jun 25, 2003
Start date
Jul 2003
Primary completion
Apr 2005
Completion
Apr 2005
Results posted
Jun 8, 2015
Last update
Jul 7, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion